Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Related Questions
How long would you recommend a woman with HR+ node-positive breast cancer treated with surgery and chemotherapy during pregnancy can breastfeed, prior to starting adjuvant endocrine therapy?
Would you give AC followed by Taxol or TC for luminal type B, clinical high risk, breast cancer?
In which patients do you offer adjuvant bisphosphates in breast cancer treatment?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Is it safe to use hormone replacement therapy in young premenopausal patients with BRCA1 mutation, triple negative breast cancer, who have undergone bilateral mastectomies and BSO without hysterectomy?
How would you discuss the prognosis of HR-positive early breast cancer in an elderly >90 patient who elects against surgery in favor of endocrine treatment only?
Would you offer endocrine therapy to a patient with T1c tumor who was initially ER+ (15%)/PR negative/HER2-1+ but changed to a triple negative phenotype after neoadjuvant chemotherapy with TC?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
How would you manage a patient who develops acute stroke during neoadjuvant chemotherapy with KEYNOTE-522 for Stage III triple negative breast cancer?
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
